Nearly all US employer-sponsored health plans responding to a large survey reported they are covering Sandoz Inc.'s biosimilar Zarxio (filgrastim-sndz) and coverage is comparable to that of its reference drug, Amgen Inc's Neupogen, and other competitors.
Ninety-four percent of plans are covering the biosimilar, according to the survey, which was conducted by Avalere Health
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?